JBIO News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

JB

Mkt Cap

$856.9M

Volume

852.45K

Next Earnings

November 12th

Loading chart

JB

JBIOJade Biosciences, Inc. Common Stock

JBIO

Pay with—

Available Balance0.00

JB

Mkt Cap

$875.1M

Volume

852.45K

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of DirectorsJade Biosciences, Inc. (Nasdaq: JBIO) announced the appointment of Dr. Mark Eisner, M.D., M.P.H., to its Board of Directors effective June 25, 2026. Dr. Eisner brings over 25 years of leadership experience in clinical development and immunology, including previous roles as Chief Medical Officer at Vir Biotechnology, Sonoma Biotherapeutics, and FibroGen, as well as 11 years at Genentech/Roche. The appointment is expected to strengthen Jade's advancement of its pipeline of antibody-based therapies for autoimmune diseases.GlobeNewswire Inc. · Jun 26, 2026

Stock Market Today: S&P 500, Dow, Nasdaq Futures Fall As House Challenges Trump's Military Authority— Broadcom, CrowdStrike In Focus (UPDATED)U.S. stock futures showed mixed performance on Thursday with the S&P 500 and Nasdaq 100 declining while the Dow Jones gained. Key movers included CrowdStrike surging on a 4-for-1 stock split announcement, Broadcom falling despite beating earnings estimates, and PVH plummeting after disappointing guidance. The House passed a war powers resolution challenging Trump's military authority in a rare bipartisan vote. BlackRock maintains an optimistic outlook on U.S. equities driven by AI sector strength and resilient corporate earnings.Benzinga · Jun 4, 2026

Jade Biosciences Announces Pricing of Public Offering of Common StockJade Biosciences (Nasdaq: JBIO), a clinical-stage biotech company focused on autoimmune diseases, announced the pricing of a public offering of 10 million shares at $15.00 per share, raising $150 million in gross proceeds. The offering is expected to close on June 5, 2026, with net proceeds to be used for clinical trials, preclinical studies, manufacturing, and R&D activities. Jefferies, TD Cowen, and UBS Investment Bank are serving as joint book-running managers.GlobeNewswire Inc. · Jun 4, 2026

Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA NephropathyJade Biosciences reported positive interim Phase 1 results for JADE101, an anti-APRIL monoclonal antibody for IgA nephropathy treatment. The drug demonstrated ~70% IgA reductions sustained at 12 weeks with a favorable safety profile and potential for every-12-week dosing. Phase 2 trials are underway with Phase 3 expected to initiate in H1 2027.GlobeNewswire Inc. · Jun 1, 2026

Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Jade Biosciences announced the appointment of Edward R. Conner, M.D., as Chief Medical Officer effective April 22, 2026. As part of the appointment, Dr. Conner received 500,000 non-qualified stock options with an exercise price of $25.38 per share, vesting over four years. The company is a clinical-stage biotech focused on autoimmune disease therapies with lead candidate JADE101 targeting APRIL for immunoglobulin A nephropathy treatment.GlobeNewswire Inc. · Apr 23, 2026

Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateJade Biosciences reported full year 2025 net loss of $127.4 million with $336.2 million in cash and investments as of December 31, 2025. The company expects cash runway into the first half of 2028. Key pipeline milestones include JADE101 Phase 1 interim data expected in Q2 2026 and Phase 2 initiation in IgA nephropathy mid-2026, JADE201 first-in-human trial in rheumatoid arthritis expected Q2 2026, and JADE301 Phase 1 trial expected in first half of 2027.GlobeNewswire Inc. · Mar 6, 2026

Jade Biosciences to Participate in Upcoming ConferencesJade Biosciences, a clinical-stage biotechnology company focused on autoimmune disease therapies, announced its participation in four major healthcare conferences in February and March 2026, including presentations at the Oppenheimer Healthcare Conference, TD Cowen Health Care Conference, Leerink Global Healthcare Conference, and Jefferies Biotech on the Beach Summit. The company's lead candidate JADE101 is in Phase 1 trials for immunoglobulin A nephropathy treatment.GlobeNewswire Inc. · Feb 11, 2026

Jade Biosciences to Participate in Upcoming ConferencesJade Biosciences, a clinical-stage biotechnology company, announced participation in multiple healthcare conferences in November 2025 and provided updates on its autoimmune disease therapy pipeline, including JADE101 and JADE201.GlobeNewswire Inc. · Nov 3, 2025

Jade Biosciences Announces $135 Million Private PlacementJade Biosciences secured a private investment in public equity (PIPE) financing of approximately $135 million, with participation from multiple healthcare investors, to fund research and development of autoimmune disease therapies.GlobeNewswire Inc. · Oct 7, 2025

Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA NephropathyJade Biosciences initiated a Phase 1 clinical trial for JADE101, a monoclonal antibody targeting APRIL for treating IgA Nephropathy. The trial aims to evaluate safety, tolerability, and potential for convenient subcutaneous dosing in healthy volunteers.GlobeNewswire Inc. · Sep 2, 2025

to start trading

JB

JBIOJade Biosciences, Inc. Common Stock

JBIO

Pay with—

Available Balance0.00

Your PositionYou don't own any JBIO yet.

Related Tickers

Earnings